Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
IDXX compared with NTLA: revenue, margins and what each company keeps, and the suppliers and customers both name
IDXX
Idexx Laboratories Inc
Change
Mkt cap
Revenue
Revenue
NTLA
Intellia Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
IDXX
Idexx Laboratories Inc
vs
NTLA
Intellia Therapeutics, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
IDXX, solid
NTLA, dashed
Supply-chain overlap
Revenue flow
NTLA: latest quarter is a loss; flow not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only IDXX
1
VNRX
Volitionrx
supplier
Shared
0
No shared counterparties.
Only NTLA
4
REGN
Regeneron Pharmaceuticals
customer
CRBU
Caribou Biosciences
supplier
—
AvenCell Therapeutics
unlisted
customer
—
SparingVision SAS
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
unlisted
customer
IDXX
Idexx Laboratories Inc
Change
676.84
▲
+0.91%
· post 677.73
· delayed
Mkt cap
$52.8B
Revenue
$1.2B
Q3 FY26
Revenue
$4.3B
FY25
NTLA
Intellia Therapeutics, Inc.
Change
11.35
▲
+2.23%
· post 11.19
· delayed
After hours
Nov 6 '26
delayed
Mkt cap
$1.6B
Revenue
$7M
Q3 FY26
Revenue
$68M
FY25
vs
Compare
After hours
Nov 6 '26
delayed
IDXX
Idexx Laboratories Inc
vs
NTLA
Intellia Therapeutics, Inc.
676.84
▲
+0.91%
post 677.73
delayed
Price
11.35
▲
+2.23%
post 11.19
delayed
$52.8B
Mkt cap
$1.6B
Q3 FY26
$1.2B
Revenue
$7M
Q3 FY26
FY25
$4.3B
Revenue
$68M
FY25
Change
Change
IDXX
676.84
▲
+0.91%
vs
NTLA
11.35
▲
+2.23%
After hours
Nov 6 '26
delayed